Published in Ther Adv Urol on December 01, 2012
Lymphovascular and neural regulation of metastasis: shared tumour signalling pathways and novel therapeutic approaches. Best Pract Res Clin Anaesthesiol (2013) 0.85
Comparing comparators: a look at control arms in kidney cancer studies over the years. Br J Cancer (2014) 0.81
A phase II study of sorafenib (BAY 43-9006) in recurrent diffuse large B cell lymphoma: an eastern cooperative oncology group study (E1404). J Hematol Oncol (2013) 0.79
The lymphatic system and pancreatic cancer. Cancer Lett (2015) 0.76
Autophagy orchestrates adaptive responses to targeted therapy in endometrial cancer. Autophagy (2017) 0.75
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med (2007) 39.39
Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med (2007) 30.94
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med (2007) 24.19
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06
Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet (2007) 15.92
Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol (2010) 13.03
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet (2011) 12.13
Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov (2006) 6.88
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. J Clin Oncol (2009) 6.86
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma. J Clin Oncol (2006) 6.77
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol (2008) 6.23
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther (2008) 5.78
Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors. J Clin Oncol (2004) 5.12
Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol (2009) 5.05
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma. J Clin Oncol (2009) 3.65
Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors. Clin Cancer Res (2005) 2.76
Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway. Semin Oncol (2006) 2.25
Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer (2010) 2.10
Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst (2008) 1.53
Cardiotoxicity induced by tyrosine kinase inhibitors. Acta Oncol (2009) 1.41
Final results of the European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS) expanded-access study: a large open-label study in diverse community settings. Ann Oncol (2011) 1.34
EORTC-GU group expert opinion on metastatic renal cell cancer. Eur J Cancer (2009) 1.28
Treatment selection in metastatic renal cell carcinoma: expert consensus. Nat Rev Clin Oncol (2012) 1.19
Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther (2011) 1.09
Sorafenib with interleukin-2 vs sorafenib alone in metastatic renal cell carcinoma: the ROSORC trial. Br J Cancer (2011) 1.08
A phase I open-label study evaluating the cardiovascular safety of sorafenib in patients with advanced cancer. Cancer Chemother Pharmacol (2010) 1.08
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy? Eur Urol (2011) 1.00
A novel preclinical strategy for identifying cardiotoxic kinase inhibitors and mechanisms of cardiotoxicity. Circ Res (2011) 0.98
A pooled analysis of sequential therapies with sorafenib and sunitinib in metastatic renal cell carcinoma. Oncology (2012) 0.98
Patient-based strategy for systemic treatment of metastatic renal cell carcinoma. Expert Rev Anticancer Ther (2010) 0.97
The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce. Crit Rev Oncol Hematol (2008) 0.94
Use of tyrosine kinase inhibitors in patients with metastatic kidney cancer receiving haemodialysis: a retrospective Italian survey. BJU Int (2012) 0.92
Safety and efficacy of sorafenib in elderly patients treated in the North American advanced renal cell carcinoma sorafenib expanded access program. Oncology (2010) 0.91
Sorafenib for the management of advanced renal cell carcinoma. Expert Rev Anticancer Ther (2011) 0.87
Experience with sorafenib and the elderly patient. Med Oncol (2009) 0.84
Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients. Expert Rev Anticancer Ther (2010) 0.83
Phase I trial to investigate the safety, pharmacokinetics and efficacy of sorafenib combined with docetaxel in patients with advanced refractory solid tumours. Eur J Cancer (2012) 0.83
Safety and efficacy of sorafenib therapy in patients with metastatic kidney cancer with impaired renal function. Clin Genitourin Cancer (2009) 0.82
Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study. Int J Clin Oncol (2010) 0.82
Second-line therapy for refractory renal-cell carcinoma. Crit Rev Oncol Hematol (2011) 0.81
Successful sorafenib treatment for metastatic renal cell carcinoma in a case with chronic renal failure. Eur Urol (2008) 0.77
A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01. Clin Transl Oncol (2010) 0.76
Sustained response following sorafenib therapy in an older adult patient with advanced renal cancer on hemodialysis: a case report. Med Oncol (2010) 0.76
XELOX (capecitabine plus oxaliplatin): active first-line therapy for patients with metastatic colorectal cancer. J Clin Oncol (2004) 3.10
Predictors of health-related quality of life and adjustment to prostate cancer during active surveillance. Eur Urol (2013) 2.84
miR-205 Exerts tumor-suppressive functions in human prostate through down-regulation of protein kinase Cepsilon. Cancer Res (2009) 2.52
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial. Lancet Oncol (2012) 2.36
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus group (EGCCCG): part I. Eur Urol (2007) 2.21
Low dose of ketoconazole in patients with prostate adenocarcinoma resistant to pharmacological castration. BJU Int (2010) 2.08
Taxanes in combination with cisplatin and fluorouracil for advanced penile cancer: preliminary results. Eur Urol (2008) 1.79
Long-term followup and clinical characteristics of testicular Leydig cell tumor: experience with 24 cases. J Urol (2006) 1.77
miR-21: an oncomir on strike in prostate cancer. Mol Cancer (2010) 1.54
Towards the definition of the best management and prognostic factors of teratoma with malignant transformation: a single-institution case series and new proposal. BJU Int (2010) 1.51
Retroperitoneal lymph node dissection with no adjuvant chemotherapy in clinical stage I nonseminomatous germ cell tumours: long-term outcome and analysis of risk factors of recurrence. Eur Urol (2010) 1.49
Peniscopically controlled CO2 laser excision for conservative treatment of in situ and T1 penile carcinoma: report on 224 patients. Eur Urol (2008) 1.49
European consensus conference on diagnosis and treatment of germ cell cancer: a report of the second meeting of the European Germ Cell Cancer Consensus Group (EGCCCG): part II. Eur Urol (2007) 1.37
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol (2006) 1.28
Sequential use of sorafenib and sunitinib in advanced renal-cell carcinoma (RCC): an Italian multicentre retrospective analysis of 189 patient cases. BJU Int (2011) 1.24
The 6-year attendance of a multidisciplinary prostate cancer clinic in Italy: incidence of management changes. BJU Int (2012) 1.11
Targeted therapies used sequentially in metastatic renal cell cancer: overall results from a large experience. Expert Rev Anticancer Ther (2011) 1.09
Treatment of collecting duct carcinoma: current status and future perspectives. Anticancer Res (2014) 1.08
Is there a role for targeted therapies in the collecting ducts of Bellini carcinoma? Efficacy data from a retrospective analysis of 7 cases. Clin Exp Nephrol (2012) 1.06
Conservative surgical therapy for leydig cell tumor. J Urol (2007) 1.02
Prognostic role of pancreatic metastases from renal cell carcinoma: results from an Italian center. Clin Genitourin Cancer (2013) 0.97
Proof of activity of anti-epidermal growth factor receptor-targeted therapy for relapsed squamous cell carcinoma of the penis. J Clin Oncol (2011) 0.95
In regard to Kagan: "The multidisciplinary clinic" (Int J Radiat Oncol Biol Phys 2005;61:967-968). Int J Radiat Oncol Biol Phys (2005) 0.90
Treatment options in hormone-refractory metastatic prostate carcinoma. Tumori (2005) 0.89
Axitinib safety in metastatic renal cell carcinoma: suggestions for daily clinical practice based on case studies. Expert Opin Drug Saf (2014) 0.87
Safety of Abiraterone Acetate in Castration-resistant Prostate Cancer Patients With Concomitant Cardiovascular Risk Factors. Am J Clin Oncol (2015) 0.87
Inhibition of the VEGF/VEGFR pathway improves survival in advanced kidney cancer: a systematic review and meta-analysis. Curr Drug Targets (2015) 0.87
Vaccination therapy in prostate cancer. Cancer Immunol Immunother (2006) 0.85
Teratoma with somatic-type malignant components in germ cell tumors of the testis: a clinicopathologic analysis of 40 cases with outcome correlation. Int J Surg Pathol (2010) 0.85
Safety and activity of sorafenib in different histotypes of advanced renal cell carcinoma. Oncology (2008) 0.84
Salvage high-dose chemotherapy in patients with germ cell tumors: an Italian experience with 84 patients. Cancer (2002) 0.83
Targeted therapies in advanced renal cell carcinoma: the role of metastatic sites as a prognostic factor. Future Oncol (2014) 0.82
Feasibility study of biweekly capecitabine, oxaliplatin, and irinotecan in patients with untreated advanced gastric cancer. Tumori (2009) 0.82
Neuroendocrine tumors of the larynx: a clinical report and literature review. Tumori (2006) 0.82
Long-term results of a combination of paclitaxel, cisplatin and gemcitabine for salvage therapy in male germ-cell tumours. BJU Int (2009) 0.82
Penile cancer. Urol Oncol (2009) 0.81
Case report: renal cell carcinoma presenting as hypertension in pregnancy. Arch Gynecol Obstet (2007) 0.80
Persistent CD30 expression by embryonal carcinoma in the treatment time course: prognostic significance of a worthwhile target for personalized treatment. J Urol (2013) 0.80
Expectations of survivors, caregivers and healthcare providers for testicular cancer survivorship and quality of life. Tumori (2011) 0.80
Optimizing further treatment choices in short- and long-term responders to first-line therapy for patients with advanced renal cell carcinoma. Expert Rev Anticancer Ther (2012) 0.79
Leydig cell tumor and hyperplasia: a review. Anal Quant Cytol Histol (2007) 0.79
Everolimus in advanced solid tumors: when to start, early or late? Tumori (2014) 0.79
Is it possible to optimize the use of targeted therapies in the treatment of renal cell carcinoma? Tumori (2011) 0.78
Clinical stage I nonseminomatous germ cell tumors of the testis in childhood and adolescence: an analysis of 31 cases. J Pediatr Hematol Oncol (2002) 0.78
IGG practice guidelines on germ cell tumor in adult male patients. Tumori (2008) 0.78
Pulmonary carcinoid tumours: indolent but not benign. Oncology (2008) 0.78
Palonosetron: an evidence-based choice in prevention of nausea and vomiting induced by moderately emetogenic chemotherapy. Tumori (2012) 0.78
Safety profile and treatment response of everolimus in different solid tumors: an observational study. Future Oncol (2014) 0.78
Time from nephrectomy as a prognostic factor in metastatic renal cell carcinoma patients receiving targeted therapies: overall results from a large cohort of patients. Oncology (2014) 0.78
Targeted therapies and survival: what we can learn from studies in advanced renal cell carcinoma. Oncology (2012) 0.77
Has dynamic sentinel node biopsy achieved its top performance in penile cancer? What clinicians still need to manage lymph nodes in early stage penile cancer. Eur Urol (2012) 0.77
Sequential Tyrosine Kinase Inhibitors (TKIs) in metastatic renal cell carcinoma: results from a large cohort of patients. Anticancer Res (2014) 0.77
Hyponatremia in cancer patients. Tumori (2015) 0.77
New perspectives in advanced genitourinary malignancies. Tumori (2012) 0.76
Long-term outcome of salvage high-dose chemotherapy in patients with germ cell tumor with poor prognostic features. Urol Oncol (2009) 0.76
Re: Peter Albers. Management of stage I testis cancer. Eur urol 2007;51:34-44. Eur Urol (2007) 0.75
Re: Roisin M. Connolly, John A. McCaffrey. High-dose chemotherapy plus stem cell transplantation in advanced germ cell cancer: a review. Eur Urol 2009;56:57-64. Eur Urol (2009) 0.75
Renal cell cancer and sorafenib: skin toxicity and treatment outcome. Tumori (2007) 0.75
Feasibility and activity for sequencing targeted therapies for the treatment of advanced renal cell carcinoma. Med Oncol (2009) 0.75
New directions for biologic targets in urothelial carcinoma--letter. Mol Cancer Ther (2012) 0.75
Prostatic metastases from testicular nonseminomatous germ cell cancer: two case reports and a review of the literature. Tumori (2013) 0.75
Complete responses in advanced renal cell carcinoma: utopia or real chance? Clin Exp Nephrol (2013) 0.75
Management of advanced genitourinary tumors. Tumori (2012) 0.75
[Focal therapy in urology: kidney cancer]. Urologia (2013) 0.75
Thyroid as a target of metastases: a case of metastatic seminoma in a patient who died of a second cancer. Tumori (2009) 0.75
pT1 penile squamous cell carcinoma: a clinicopathologic study of 56 cases treated by CO2 laser therapy. Anal Quant Cytol Histol (2009) 0.75